These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 17996417)
1. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone. Cobo J; Morosini MI; Pintado V; Tato M; Samaranch N; Baquero F; Cantón R Diagn Microbiol Infect Dis; 2008 Mar; 60(3):319-22. PubMed ID: 17996417 [TBL] [Abstract][Full Text] [Related]
2. Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. Stone NR; Woodford N; Livermore DM; Howard J; Pike R; Mushtaq S; Perry C; Hopkins S J Antimicrob Chemother; 2011 Nov; 66(11):2677-8. PubMed ID: 21846669 [No Abstract] [Full Text] [Related]
3. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Rodríguez-Avial C; Rodríguez-Avial I; Merino P; Picazo JJ Clin Microbiol Infect; 2012 Jan; 18(1):61-6. PubMed ID: 21722259 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Cha R Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108 [TBL] [Abstract][Full Text] [Related]
5. The effect of amikacin and imipenem alone and in combination against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Máthé A; Szabó D; Anderlik P; Rozgonyi F; Nagy K Diagn Microbiol Infect Dis; 2007 May; 58(1):105-10. PubMed ID: 17300908 [TBL] [Abstract][Full Text] [Related]
6. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. Psichogiou M; Tassios PT; Avlamis A; Stefanou I; Kosmidis C; Platsouka E; Paniara O; Xanthaki A; Toutouza M; Daikos GL; Tzouvelekis LS J Antimicrob Chemother; 2008 Jan; 61(1):59-63. PubMed ID: 17999975 [TBL] [Abstract][Full Text] [Related]
7. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance. Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360 [TBL] [Abstract][Full Text] [Related]
8. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. Conejo MC; Hernández JR; Pascual A Diagn Microbiol Infect Dis; 2008 Jul; 61(3):343-5. PubMed ID: 18339509 [TBL] [Abstract][Full Text] [Related]